alexanderbelcrediJun 17, 2021PhagoMed named a Finalist in Extreme Tech Challenge 2021PhagoMed has been named a Healthcare Category Finalist in the Extreme Tech Challenge 2021. The company was selected out of more than...
alexanderbelcrediMay 5, 2021PhagoMed graduates from NYU Stern School of Business EFL programAmong more than 500 applicants, PhagoMed was selected in autumn 2020 to participate in the Endless Frontiers Lab (EFL) acceleration...
alexanderbelcrediApr 7, 2021Published: ɛ2-phages are naturally bred and vastly superior to wild-typePhagoMed published details on its phage program PM-399 including a detailed introduction to its proprietary ɛ2-(evolution...
alexanderbelcrediMar 29, 2021First patient successfully treated with ε2 phagePhagoMed partnered with Yale University and the University of Maryland School of Medicine to provide intra-articular phage therapy to a...
alexanderbelcrediFeb 25, 2021PhagoMed selected for Phase III of EIT Health's Gold Track programSince June 2020, PhagoMed has been part of the Gold Track program, the premier European life sciences accelerator. Following the...
alexanderbelcrediJan 13, 2021Published: Breakthrough therapy for recurrent bacterial vaginosisAn engineered phage endolysin could offer a highly innovative and precise therapy for recurrent bacterial vaginosis, a disease for which...
alexanderbelcrediDec 4, 2020PhagoMed Selected as Leading Young European Biotech CompanyPhagoMed Biopharma GmbH came 2nd and won €20.000 in one of the toughest contests for young European biotech companies, namely the Health...
alexanderbelcrediNov 17, 2020PhagoMed wins Medical Biotech track at Hello Tomorrow competitionEarlier this year, PhagoMed was selected to compete at the Hello Tomorrow Global Challenge 2020 in 'Medical Biotech' track. The...
alexanderbelcrediOct 28, 2020Pre-Print: Novel solution for recurrent bacterial vaginosis published on MedRxivPress Release, Vienna (Austria), 28th October 2020: An engineered phage endolysin could offer a highly innovative and precise therapy for...